A Clinical Study Playbook in the context of Real-World Evidence (RWE) studies is a comprehensive roadmap designed to streamline the planning, execution, and management of non-interventional studies. The use of a playbook in RWE studies brings several benefits:
- Standardisation and Consistency: A playbook provides standardized protocols and procedures, ensuring consistency across different stages of a study. This is crucial for non-interventional studies that rely on real-world data, as it minimizes variability and enhances the reliability of the results.
- Regulatory Compliance: With the complex regulatory landscape surrounding RWE studies, a playbook can help ensure that all aspects of the study (including regulatory classification) are compliant with local and international regulations. This is crucial for the acceptance and publication of the study findings (e.g., compliance with the ICJME Recommendations).
- Improved Collaboration: A playbook helps to facilitate better understanding of the study type, regulatory requirements, and operational considerations. This in turn helps communication and collaboration due to the clear guidelines and expectations set out in the playbook, which everyone can follow.
- Efficiency and Time Savings: By having a predefined set of guidelines and best practices, a playbook can significantly reduce the time needed for planning and executing studies. This helps in faster initiation and completion of studies, which is particularly beneficial for timely decision-making based on RWE.
- Quality Assurance: The playbook acts as a quality assurance tool, outlining the necessary steps and considerations to maintain high standards of research. This includes data integrity, ethical considerations, and regulatory compliance, which are essential for the credibility of RWE studies.
- Risk Management: The playbook can identify potential risks and challenges associated with non-interventional studies (e.g., verification of valid consent) and suggest mitigation strategies, such as monitoring. This proactive approach to risk management is critical for the smooth conduct of RWE studies, minimising disruptions and ensuring data validity.
- Enhanced Data Utilisation: In RWE studies, leveraging real-world data effectively is key. A playbook can provide guidelines on data collection, management, and analysis techniques that are best suited for non-interventional studies, ensuring that the data collected is used to its full potential.
- Scalability: A well-designed playbook allows for scalability, meaning it can be adapted and applied to various types of non-interventional studies and across different countries. This flexibility is a significant advantage in the rapidly evolving field of RWE research.
In summary, a clinical study playbook (or roadmap) is a valuable tool that enhances the efficiency, reliability, and quality of non-interventional studies. It fosters standardisation, facilitates regulatory compliance, ensures data integrity, and promotes effective collaboration, making it an indispensable resource in this field of clinical research.
Share this story...
Germany – AKEK – Secondary Use of Patient Data for Research Purposes
RWE 201 - Germany – AKEK – Secondary Use of Patient Data for Research Purposes AKEK Statement (Aug 2023): https://www.akek.de/wp-content/uploads/Stellungnahme-EHDS_V7.1.pdfThe Working Group of Medical Ethics Commissions in Germany (AKEK) [...]
UK – NHS England – Federated Data Platform – Lessons Learned from the General Practice Data for Planning and Research Initiative
RWE 201 - UK – NHS England – Federated Data Platform – Lessons Learned from the General Practice Data for Planning and Research Initiative NHS England – Federated Data [...]
UK – NICE – RWE Framework
RWE 201 - UK – NICE – RWE Framework NICE RWE Framework: https://www.nice.org.uk/corporate/ecd9/chapter/overviewReal-world data (RWD) encompasses various types of information on patient health, care delivery, and experiences collected outside [...]
UK – MHRA – Randomised Controlled Trials Using Real World Data
RWE 201 - UK – MHRA – Randomised Controlled Trials Using Real World Data MHRA RWD Guidance: https://www.gov.uk/government/publications/mhra-guidance-on-the-use-of-real-world-data-in-clinical-studies-to-support-regulatory-decisions/mhra-guideline-on-randomised-controlled-trials-using-real-world-data-to-support-regulatory-decisions The MHRA guideline focuses on sponsors planning to [...]
UK – MHRA – Use of RWD to Support Regulatory Decisions
RWE 201 - UK – MHRA – Use of RWD to Support Regulatory Decisions MHRA RWD Guidance: https://www.gov.uk/government/publications/mhra-guidance-on-the-use-of-real-world-data-in-clinical-studies-to-support-regulatory-decisions/mhra-guidance-on-the-use-of-real-world-data-in-clinical-studies-to-support-regulatory-decisions The MHRA (Medicines and Healthcare products Regulatory Agency) [...]
Real World Evidence (RWE) 201 – France – Haute Autorité de Santé (HAS) – Real World Study Guide
RWE 201 - France – Haute Autorité de Santé (HAS) – Real World Study Guide HAS Real World Stidy Guide: https://www.has-sante.fr/upload/docs/application/pdf/2021-06/real-world_studies_for_the_assessment_of_medicinal_products_and_medical_devices.pdfThe Haute Autorité de Santé (HAS), France's National Authority [...]







